Printer Friendly
The Free Library
19,595,263 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

AmeriGas Elects Marvin O. Schlanger to Its Board of Directors; Stratton Retires.


VALLEY FORGE, Pa. -- AmeriGas Propane, Inc., general partner of AmeriGas Partners, L.P. (NYSE:APU), reported that Marvin O. Schlanger, 60, has been elected a director. Schlanger has been a director of UGI Corporation, a 44% owner of AmeriGas Partners, since 1998. Schlanger is a principal in the firm of Cherry Hill Chemical Investments, LLC, a supplier of management services and capital to chemical and allied industries. He is also Vice Chairman of Hexion Specialty Chemicals, Inc., and a director of Momentive Performance Materials Inc. and UGI Utilities, Inc.

Concurrently, James W. Stratton retired from the AmeriGas board after nearly 15 years of service. Lon R. Greenberg, chairman of AmeriGas, said, "Jim Stratton has been an invaluable member of the AmeriGas board since the inception of the Partnership in 1995. We thank him for his thoughtful contributions and wish him well in retirement."

"Marv Schlanger has represented UGI shareholders very well for many years and I'm certain he will represent AmeriGas unitholders with equal distinction," continued Greenberg.

AmeriGas Partners is the nation's largest retail propane marketer, serving nearly 1.3 million customers from over 600 locations in 46 states. UGI Corporation (NYSE:UGI), through subsidiaries, owns 44% of the Partnership and public unitholders own the remaining 56%.

Comprehensive information about AmeriGas is available on the Internet at http://www.amerigas.com.

COPYRIGHT 2009 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jan 28, 2009
Words:221
Previous Article:Philip Morris International Inc. to Host Webcast of 2008 Fourth-Quarter and Full-Year Results.
Next Article:Can-Fite Completed Patient Enrollment for the Phase II Trial in Dry Eye Syndrome with CF101.
Topics:

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles